Expanding Veterans’ Access to Psychedelics for Mental Health Treatment

The Trump administration initiated efforts to broaden veterans’ access to psychedelic drugs for treating post-traumatic stress disorder (PTSD) and depression. Key figures indicate that up to 2.1 million veterans could benefit from these treatments, such as psilocybin from ‘magic mushrooms’ or MDMA, as per Andrew Gradison of the Veterans Health Administration.

Gradison highlighted that around 6.4 million veterans depend on the Department of Veterans Affairs (VA) for healthcare. Many veterans face challenges with PTSD that affect various aspects of life, including sleep and relationships. Christopher DiViaio, clinical director at Eleve Behavioral Health, mentioned that while traditional treatments help some, they do not work for everyone. Psychedelic-assisted therapy is being explored as an alternative.

Currently, psychedelic drugs lack federal approval as safe treatments for mental health conditions. This presents obstacles for the VA, even with potential future approvals. President Trump issued an executive order to expedite research and access to psychedelic therapies. However, the FDA has yet to approve such therapies. In 2024, under the Biden administration, the FDA rejected the use of MDMA combined with therapy for PTSD treatment.

Veterans have become a focus in psychedelic treatment research given the need for new approaches to mental health. Gradison suggested increasing the VA’s capability to offer these therapies to a substantial portion of its patients.

Approximately one-third of regular VA patients have mental health conditions like PTSD or depression. This makes psychedelic therapies a possible option for about 2.1 million veterans under VA care. Toby Marton, chief medical officer at Radial Health, stated that the VA is committed to this initiative, already identifying sites for pilot programs.

Despite this commitment, Gradison noted challenges in treating many patients within the first year using FDA-approved psychedelic drugs, citing practical limits. The demand for these therapies is expected to exceed available supply.

Experts emphasize that the goal is not to broadly distribute unapproved psychedelics. Efforts focus on accelerating legal and research processes to make approved treatments available to VA patients. Marton explained veterans lobby for these developments, driven by widespread PTSD exacerbated by military service. Existing treatments fall short.

The VA is engaged in 20 clinical trials involving psychedelics. Trump’s executive order also directed focus on ibogaine, another potential treatment for veteran conditions, though it remains a controlled substance. Trump characterized veteran suicide as a tragedy and regarded psychedelic treatments as having potential impact. He expressed hope for their positive effects.

Health and Human Services Secretary Robert F. Kennedy Jr. stated the government must explore treatment options due to many veterans seeking therapy abroad. Kennedy expressed concern over the lack of domestic treatment avenues for promising interventions.

Psychedelic Drugs Face FDA Hurdles

The main challenge remains securing FDA approval for these treatments. In 2024, the FDA declined an application for MDMA-assisted psychotherapy for PTSD. Nonetheless, the Trump administration implemented regulatory measures to speed up other psychedelic therapy developments.

Following Trump’s order, the FDA fast-tracked reviews for three companies working on psychedelic treatments. One such treatment is Compass Pathways’ synthetic psilocybin for resistant depression, expected to seek FDA approval soon. Even with approval, the VA would need to expand capacity to meet veteran demand.

Psychedelic therapy’s appeal lies in its potential to aid suffering veterans, though it’s not a universal remedy. DiViaio advised caution, noting the intense emotions these therapies may provoke. It is crucial to identify who benefits, who is at risk, and the support needed at all stages of treatment.

Future Steps

If FDA approvals occur, the administration must then make these treatments accessible within the VA. DiViaio stressed the importance of evidence and safeguards before proposing psychedelic-assisted treatments as viable options. Discussing affordability, professional availability, and patient care post-treatment is necessary, as promising trials do not guarantee everyday accessibility.

Newsweek’s AI platform, Martyn, assisted in creating this article.